Press release content from Globe Newswire. The AP news staff was not involved in its creation.
VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce .
Amarin Corporation plcMarch 17, 2021 GMT
28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk
Consistent reductions in overall stroke and in ischemic stroke observed across multiple subgroups
Administration of pure icosapent ethyl, VASCEPA, represents a novel clinical approach to stroke reduction
REDUCE-IT® STROKE abstract receives prestigious Paul Dudley White International Scholar Award to recognize the authors with the highest ranked abstract from the United States at the International Stroke Conference 2021
Share:
28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk
Consistent reductions in overall stroke and in ischemic stroke observed across multiple subgroups
Administration of pure icosapent ethyl, VASCEPA, represents a novel clinical approach to stroke reduction
REDUCE-IT® STROKE abstract receives prestigious Paul Dudley White International Scholar Award to recognize the authors with the highest ranked abstract from the United States at the International Stroke Conference 2021
DUBLIN, Ireland and BRIDGEWATER, N.J., March 17, 2021 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ:AMRN) today announced the presentation of REDUCE-IT® STROKE at the International Stroke Conference 2021, being held virtually from March 17 – March 19, 2021,
Share this article
Share this article
NEW YORK, March 15, 2021 /PRNewswire/ One of the key reasons behind the growth of the global
external defibrillator market is the rise in the prevalence of cardiovascular diseases (CVDs). As a result, the revenue generated from the sale of such devices is predicted to reach $9,450.3 million by 2030, from $3,926.5 million in 2019, at an 8.5% CAGR between 2020 and 2030, according to P&S Intelligence.
According to the
Heart Disease and Stroke Statistics 2017 Update report published by the American Heart Association (AHA), 800,000, or one in every three deaths in the U.S, is a direct result of CVDs. Defibrillators prove helpful in cardiac emergencies, by sending an electric shock to neutralize the abnormal current flowing through the sinoatrial and atrioventricular nodes, thus restoring the normal heart rhythm.
#GoRedForWomen: National Wear Red Day raises awareness of heart health
Cardiovascular disease leading killer of women in the US
Tags:
Are you familiar with the connection between your cardiovascular health and COVID-19? (Photo used with permission from Heart & Vascular Institute)
DETROIT – Cardiovascular disease is the leading killer of women in the United States, according to the American Heart Association.
According to the association’s newly released 2021 Heart Disease and Stroke Statistics, heart disease kills one woman approximately every 80 seconds. Cardiac events are on the rise in women in their 20s.
The association is calling on women to spread awareness about cardiac health on Friday, which is National Wear Red Day. Women and men are encouraged to “wear red and give” as part of the Go Red For Women movement.